Roche’s Tecentriq (atezolizumab) + Abraxane Receives CHMP’s Recommendation for its Approval in Europe

 Roche’s Tecentriq (atezolizumab) + Abraxane Receives CHMP’s Recommendation for its Approval in Europe

Roche’s Tecentriq (atezolizumab) + Abraxane Receives CHMP Recommendation for its Approval in Europe

Shots:

  • The CHMP recommendation is based on P-III IMpassion130 study results assessing Tecentriq + Abraxane vs PBO + Abraxane in patients with 902 patients in ratio (1:1) with unresectable LA or m-TNBC with no prior treatment for m-breast cancer
  • The P-III Impassion130 results: m-PFS (7.5 vs 5.0 mos.); OS in PD-L1-positive population (25.0 vs 18.0 mos.); OS in IIT population (21.0 vs 18.7 mos.)
  • Tecentriq is a mAb targeting PD-L1, blocking its interaction with PD-1 and B7.1 receptor, thus enabling the interaction of T-cells and is an approved therapy in the US & EU as monothx. or combination therapy for NSCLC, SCLC, m-UC and PD-L1+ triple-negative breast cancer

Click here to read full press release/ article | Ref: Roche | Image: Chicago Tribune

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post